Genetic Analysis strengthens and future-proofs the organization

OSLO, NORWAY, January 31, 2023 – Molecular diagnostics specialist, Genetic Analysis AS (“GA”) is happy to announce that GA is strengthening and future-proofing the organization within business development, sales, and product development to be better positioned to harvest opportunities in the microbiome market. As diagnostics is now becoming a vital part of the treatment regime for gastroenterological disorders, GA believes that the microbiome diagnostic market will continue to rapidly increase in the coming years.  Following the recent regulatory approval of microbiome-altering drugs in the US, GA also sees a significant increase in opportunities to add several new markers on the GA-map® platform.

The business development function will initially have a specific focus on building a business on the GA-map® platform towards labs in the US, as well as focus on the significant opportunity that microbiome-altering drugs represent for GA as a diagnostics player.

GA is therefore pleased to announce that GA’s Chief Technology Officer Kari Furu has accepted the new position as Head of Business and Product Development. Kari and GA’s development teams have developed world-leading innovative products for GA, and its product development within IBD attracted strong interest recently as a finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD.

We are also happy to announce an addition to the management team, Mr. Detlef Janke, who has accepted the position of Commercial Director. Detlef has more than 30 years of experience in commercial and management positions in the diagnostic industry with companies like Bio-Rad, Axis-Shield, and Gentian. Detlef is based in Germany and has been with GA since 2015. Detlef will focus on further commercialization of our GA-map® platform.

GA is also happy to announce that Ms. Pranvera Hiseni has accepted the position of Development Manager, reporting to the Head of Business and Product Development, where she will be responsible for GA’s development projects. Pranvera has worked in GA’s development department with a key focus on platform development and has also been instrumental in building up the HumGut Database, a comprehensive human gut metagenome collection.

After the implementation of the new organization, the management team will consist of:

  • Ronny Hermansen (CEO)
  • Eilert Aamodt (CFO)
  • Cristina Casén (Senior VP Clinical & Medical Affairs)
  • Lars Tiller (Head of Operations)
  • Kari Furu (Head of Business and Product Development)
  • Detlef Janke (Commercial Director)

With these new organizational changes, the previous responsibilities of the CTO and CCO will be implemented under the Product and Software development team and the clinical team.
The new organization will be implemented immediately.

Ronny Hermansen, CEO of Genetic Analysis, comments:
“I am happy to announce that Ms. Kari Furu and Mr. Detlef Janke have accepted to join the GA management team with a core focus on business development and sales. I am also happy to announce that Pranvera Hiseni has accepted to take a leading role in GA’s development function. GA sees the increasing awareness around our product offerings and research within the Microbiome field, and by focusing on our organisation, GA will take a strong position in this booming market. Ms. Anita Patel Jusnes, former CCO, has accepted a new position in the pharma industry, and I thank her for the outstanding work she has done for GA over the last few years, where she has been instrumental in the commercialization of the GA-map®.”

Please read the full press release in English:

Please read the translated press release in Swedish: